Novartis Sees Sales Growth Through Next Round of Patent Expirations — Update
By Adria Calatayud
Novartis sought to reassure investors that its sales can continue to grow through an upcoming round of patent expirations, projecting steady rises over the next five years and signaling potential gains from artificial intelligence.
The Swiss drugmaker is deploying AI across its research-and-development, manufacturing and commercial operations, and the technology is showing promise to conduct clinical trials faster and with a greater probability of success, Chief Executive Vas Narasimhan told investors at an event in London on Thursday.
Over time, Novartis aims to increase the probability of success of the medicines it tests in trials with humans to 12%, compared with the current industry average of 8%, through a better design using AI, Narasimhan said. It also wants to shorten drug cycle times to eight years from the industry average of 12 years, he added.
Narasimhan--who sits on the board of Claude AI chatbot maker Anthropic--said on a call with reporters that AI would help drive up productivity in Novartis's manufacturing and commercial operations in the near term, and that research-and-development speed and efficacy benefits would take longer to materialize.
Recent setbacks in clinical trials have put Novartis's long-term growth outlook on investors' radars.
The company is due to lose U.S. patent protection for key drugs such as anti-inflammatory drug Cosentyx, breast-cancer medicine Kisqali and multiple-sclerosis treatment Kesimpta between 2029 and 2031, and some of the products it previously saw as potential future growth drivers fell short in their pivotal studies.
Investors' concerns are surfacing just as the company is returning to sales growth after another wave of expirations--including that of heart drug Entresto--hurt its top and bottom lines over the past year.
"This company has a track record of generating innovations that allow it to grow through these periods, and my full expectation is we will grow through that 2030 period," Narasimhan said at Thursday's investor event.
Novartis forecast annual sales growth of 5% from 2026 to 2031, excluding the effect of currency movements. It had previously forecast annual sales growth in the 5% to 6% range over the 2025-30 period.
Shares in Novartis were down 3.2% in European midday trading.
Novartis raised its peak sales estimates for Kesimpta, as well as Scemblix and Leqvio, saying this reinforced confidence in the company's midterm outlook.
The company said it now has nine in-market products with potential to generate annual peak sales of between $3 billion and $10 billion, as well as 10 in late-stage development that could bring in multibillion-dollar sales at their peak. It expects its drug pipeline to support sustained mid-single-digit growth in the long run.
Narasimhan said the company would continue to target acquisitions predominantly below $2 billion in value, while selectively pursuing larger deals.
Novartis said it is on track to return to a core operating profit margin above 40% by 2029, as previously indicated.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 19, 2026 07:49 ET (12:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

The 10 Best Dividend Stocks

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

